Zydus gets USFDA's orphan drug designation for beta-thalassemia product
Published on: Nov. 6, 2025, 3:25 p.m. | Source: Daily Excelsior
NEW DELHI, Nov 6: Zydus Lifesciences on Thursday said the US health regulator has granted Orphan Drug Designation (ODD) to Desidustat, a novel product for the treatment of beta-thalassemia. The US Food and Drug Administration (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. “This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop Desidustat to address beta-thalassemia,” Zydus […]
